Breaking the Barrier: CD8+ T cells in Atopic Dermatitis and Psoriasis Vulgaris

Completed

Conditions: atopic dermatitis
10014982
eczema
10001708

Registration Number: NL-OMON32531

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 36

Inclusion Criteria

Atopic dermatitis patients:
- Adult (18-70 years of age) male or female patients diagnosed with atopic dermatitis
- Positive APT to house dust mite allergen
- Biopsy location (~4 cm2) should not be treated with topical steroids for at least 1 week
- No use of oral antihistamines in the 2 weeks prior to inclusion;Psoriasis vulgaris patients:
- Adult (18-70 years of age) male or female patients diagnosed with psoriasis vulgaris
- Biopsy location (~4 cm2) should not be treated with topical steroids for at least 1 week;Healthy controls:
- Adult (18-70 years of age) male or female volunteers without a history of skin diseases
- Biopsy location (~4 cm2) should not be treated with topical steroids for at least 1 week
- No history of asthma and/or hay fever

Exclusion Criteria

- Use of systemic immunosuppressive drugs (i.e., cyclosporin, prednisolone, methotrexate, neotigason, fumaric acid) in the 6 weeks prior to inclusion
- Exposure of biopsy location to (extraordinary) UV sunlight (i.e. UV-therapy, sunny holiday) in the weeks prior to inclusion
- (Secondary) skin infection

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>We will determine the percentage of CD8+ IL-13-producing skin resident T cells<br /><br>in acute and chronic AD using the APT as an in vivo model. Results will be<br /><br>compared to data from lesional and non-lesional AD, PV skin and healthy control<br /><br>skin. </p><br>

Secondary Outcome Measures